[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-cancer-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-cancer-tumor":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988",false,"NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","3 Years","OBSERVATIONAL","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":65,"type":66},"2026-06-09","ACTUAL",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2030-12-31",{"name":72,"class":73},"Mark C Burgmans, MD PhD","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100575626","development-of-a-radiomics-model-with-mr-to-predict-the-occurence-of-a-infiltration-of-muscoskeletal-tumor-100575626","NCT06774729","Development of a Radiomics Model With MR to Predict the Occurence of a Infiltration of Muscoskeletal Tumor","Development of a Radiomics Model With 3T Multiparametric MR to Predict the Occurence of a Perilesional Infiltration of Muscoskeletal Tumor During the Pre- Surgery Planning","Inclusion Criteria:\n\n* Age over 18\n* suspect of soft tissue sarcoma with a indication for surgical treatment\n* suspect of bone cancer tumor with a indication for surgical treatment\n* To give informed consent\n\nExclusion Criteria:\n\n* simultaneous cancer or history of cancer in the last 5 years\n* acute or chronic serious conditions that could\n* contraindication to conduct a Contrast-enhanced magnetic resonance imaging (MRI) such as:\n\n  * renal failure without dialysis\n  * history of allergy to a paramagnetic contrast agent\n  * claustrophobia\n  * symptomatic epilepsy or history of epilepsy\n  * cardiac pacemaker\n  * infusion pump, prosthesis or any implant not compatible with MRI\n  * pregnancy",{"count":83,"type":21},122,"2 Years","The goal of this observational study is to evaluate the feasibility and clinical utility of radiomics to diagnose peri-lesion tumour infiltration of tumours in participants with a suspect of Bone Cancer Tumor or Soft Tissue Sarcoma (STS).\n\nThe main questions it aims to answer are:\n\n* is radiomics able to identify the ratio of participants truly diagnosed as positive to all those who had positive test results?\n* is radiomics able to identify the likelihood that a participant who has a negative test result indeed does not have the disease?\n\nParticipants eligible for this study will get a MRI as part of their regular medical care. The only difference is that their data will be recorded and anonymously analyzed.",[87,29],"Soft Tissue Sarcoma (STS)","RECRUITING","2025-01-09",{"date":91,"type":66},"2025-01-14",{"date":93,"type":21},"2025-03",{"date":95,"type":21},"2028-10",{"name":97,"class":73},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",1]